Study of the Effect on Non-small Cell Lung Cancer of the Investigational Drug Motexafin Gadolinium When Used in Combination With Docetaxel (Taxotere)
Phase II Trial of Motexafin Gadolinium and Docetaxel for Second Line Treatment of Patients With Advanced Non-small Cell Lung Cancer
Sponsor: Pharmacyclics LLC.
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Pharmacyclics LLC.
- Acute Myeloid Leukemia (AML) · Phase PHASE2 · Apr 2017
- Non-Small Cell Lung Carcinoma · Phase PHASE2 · Jun 2008
- Leukemia · Phase PHASE2
- Head and Neck Cancer · Phase PHASE1
- Chronic Lymphocytic Leukemia · Phase PHASE2
More terminations from Pharmacyclics LLC.
A PHASE2 clinical study on Lung Cancer, this trial is terminated or withdrawn. The trial is conducted by Pharmacyclics LLC. and has accumulated 7 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
May 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pharmacyclics LLC.
For direct contact, visit the study record on ClinicalTrials.gov .